Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Articles published by Xencor, Inc. < Previous 1 2 Next > Xencor Presents Early Clinical Data from Combination Study of Vudalimab and New Data from Multiple Preclinical-stage XmAb® Programs at the SITC Annual Meeting November 10, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor Reports Third Quarter 2022 Financial Results November 07, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor’s IL2-Fc Cytokine, XmAb®564, is Well-tolerated and Selectively Expands Regulatory T Cells in Phase 1a Clinical Study November 07, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor to Present New Clinical Data from the Phase 1 Study of Plamotamab in Relapsed or Refractory Non-Hodgkin’s Lymphoma at the American Society of Hematology Annual Meeting November 03, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor to Host Third Quarter 2022 Financial Results Webcast and Conference Call on November 7, 2022 October 31, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor to Present Seven Posters on Multiple Clinical Trials and Research-stage Programs at the SITC Annual Meeting October 05, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor Appoints Nancy Valente, M.D., to Board of Directors September 09, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor Reports Second Quarter 2022 Financial Results August 03, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor to Host Second Quarter 2022 Financial Results Webcast and Conference Call on August 3, 2022 July 27, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®104, PD-1 x ICOS Bispecific Antibody, in Advanced Solid Tumors May 26, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor Reports First Quarter 2022 Financial Results May 05, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor to Host First Quarter 2022 Financial Results Webcast and Conference Call on May 5, 2022 April 28, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor Presents Data from Multiple Preclinical XmAb® Cytokine Programs at the American Association for Cancer Research (AACR) Annual Meeting 2022 April 08, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor Reports Fourth Quarter and Full Year 2021 Financial Results February 23, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor to Report Fourth Quarter and Full Year 2021 Financial Results and Host Conference Call on February 23, 2022 February 16, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor to Present at Upcoming Investor Conferences February 02, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor Highlights 2022 Corporate Priorities and Portfolio Milestones January 11, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor to Present at the H.C. Wainwright Bioconnect Virtual Conference January 06, 2022 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor Presents Data from Phase 1 Study of Plamotamab in B-cell Non-Hodgkin Lymphomas at the ASH Annual Meeting December 12, 2021 From Xencor, Inc. Via Business Wire Tickers XNCR Zenas BioPharma Acquires Exclusive Worldwide Rights to Obexelimab from Xencor November 21, 2021 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor to Present at Upcoming Investor Conferences November 19, 2021 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor Presents Updated Data from the Phase 1 Study of Vudalimab, PD-1 x CTLA-4 Bispecific Antibody, at the SITC Annual Meeting November 12, 2021 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor Presents Data from Multiple Preclinical XmAb® Bispecific Antibody Programs and IL-12 Cytokine, XmAb662, at the SITC Annual Meeting November 12, 2021 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor Reports Third Quarter 2021 Financial Results and Announces Encouraging Preliminary Data from Ongoing Phase 1 Study of Potency-reduced IL15-Fc Cytokine, XmAb306 November 08, 2021 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor to Present Data from the Phase 1 Study of Plamotamab in B-Cell Malignancies at the American Society of Hematology Annual Meeting November 04, 2021 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor Presents Clinical Data from the Phase 1 Study of Tidutamab in Neuroendocrine Tumors at NANETS’ Multidisciplinary NET Medical Virtual Symposium November 03, 2021 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor to Present at Upcoming Investor Conferences November 02, 2021 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor to Host Third Quarter 2021 Financial Results Webcast and Conference Call on November 8, 2021 November 01, 2021 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor Enters Global Collaboration and License Agreement With Janssen to Advance Plamotamab and XmAb CD28 Bispecific Antibody Combinations for the Treatment of Patients With B-Cell Malignancies October 04, 2021 From Xencor, Inc. Via Business Wire Tickers XNCR Xencor to Present Data from the Phase 1 Study of Vudalimab (XmAb®717) and Four Research Programs at the SITC Annual Meeting October 01, 2021 From Xencor, Inc. Via Business Wire Tickers XNCR < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.